🇺🇸 FDA
Pipeline program

Ozempic 1 mg solution for injection in pre-filled pen, Semaglutide Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen, Ozempic 0.25 mg solution for injection in pre-filled pen

NN6535-7519

Phase 3 small_molecule active

Quick answer

Ozempic 1 mg solution for injection in pre-filled pen, Semaglutide Placebo, Ozempic 0.5 mg solution for injection in pre-filled pen, Ozempic 0.25 mg solution for injection in pre-filled pen for Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Novo Nordisk A/S
Indication
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials